Investor
GREAT POINT PARTNERS LLC
CIK 0001281446 · filed 2026-05-15 · SEC filing
13F book
$435.1M
Positions
39
18 new · 8 sold
Largest name
7.2%
Apogee Therapeutics, Inc. · APGE
Est. mark
$36.1M
Price effect on 21 names still held. Flow $63.7M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. | APGE | 374K | $31.5M | 7.2% | $3.25M | Held |
| Vor Biopharma Inc. | VOR | 1.75M | $31.2M | 7.2% | $6.52M | Added$13.3M |
| Zura Bio Ltd | ZURA | 4.22M | $25.1M | 5.8% | $2.71M | Added$5.09M |
| Amylyx Pharmaceuticals, Inc. | AMLX | 1.75M | $24.3M | 5.6% | $3.19M | Held |
| Nektar Therapeutics | NKTR | 316.5K | $22.8M | 5.2% | $6.25M | Added$13.9M |
| Sol-Gel Technologies Ltd. | SLGL | 274.4K | $21.7M | 5.0% | — | New |
| Alumis Inc. | ALMS | 856.1K | $18.9M | 4.3% | — | New |
| Bright Minds Biosciences Inc. | DRUG | 220K | $16.1M | 3.7% | — | New |
| Annexon, Inc. | ANNX | 2.5M | $13.8M | 3.2% | — | New |
| Kalvista Pharmaceuticals Inc | — | 675K | $13.6M | 3.1% | $2.69M | Cut$2.51M |
| Immunovant, Inc. | IMVT | 545.6K | $13.6M | 3.1% | −$316.5K | Cut−$5.51M |
| Jade Biosciences, Inc. | JBIO | 964.5K | $13.6M | 3.1% | −$1.11M | Added$1.11M |
| Contineum Therapeutics, Inc. | CTNM | 800.2K | $10.5M | 2.4% | $1.3M | Added$1.31M |
| Zenas BioPharma, Inc. | ZBIO | 524.1K | $10.2M | 2.4% | — | New |
| Neurogene Inc. | NGNE | 500K | $10.1M | 2.3% | −$154K | Added$2.87M |
| Moonlake Immunotherapeutics | MLTX | 500K | $9.32M | 2.1% | — | New |
| Climb Bio, Inc. | CLYM | 1.33M | $9.14M | 2.1% | $2.79M | Added$5.22M |
| Oruka Therapeutics, Inc. | ORKA | 183.3K | $8.99M | 2.1% | $3.44M | Held |
| Eupraxia Pharmaceuticals Inc. | EPRX | 1.2M | $8.69M | 2.0% | −$372K | Held |
| Vera Therapeutics, Inc. | VERA | 199.3K | $8.02M | 1.8% | — | New |
| Evommune, Inc. | EVMN | 325K | $7.47M | 1.7% | $1.91M | Held |
| Lb Pharmaceuticals Inc | LBRX | 300K | $7.4M | 1.7% | — | New |
| Compass Therapeutics, Inc. | CMPX | 1.35M | $7.14M | 1.6% | — | New |
| Scynexis Inc | SCYX | 7.55M | $6.93M | 1.6% | — | New |
| Palisade Bio, Inc. | PALI | 3.41M | $5.96M | 1.4% | — | New |
| Context Therapeutics Inc. | CNTX | 2.24M | $5.86M | 1.3% | $2.57M | Cut−$1.02M |
| Relmada Therapeutics, Inc. | RLMD | 842.1K | $5.86M | 1.3% | — | New |
| Silence Therapeutics Plc | — | 1.02M | $5.38M | 1.2% | −$654.5K | Added$465.1K |
| Unicycive Therapeutics, Inc. | UNCY | 796.6K | $5.24M | 1.2% | $645.2K | Held |
| Tenax Therapeutics, Inc. | TENX | 327.3K | $5.23M | 1.2% | — | New |
| ProMIS Neurosciences Inc. | PMN | 371.4K | $4.72M | 1.1% | — | New |
| Cullinan Therapeutics, Inc. | CGEM | 300K | $4.26M | 1.0% | $1.16M | Cut−$2.3M |
| Immix Biopharma, Inc. | IMMX | 350K | $3.19M | 0.7% | — | New |
| Rezolute, Inc. | RZLT | 951.8K | $2.9M | 0.7% | $656.7K | Held |
| Pharvaris N.V. | PHVS | 82.8K | $2.34M | 0.5% | $41.4K | Held |
| Humacyte Inc | — | 3.75M | $2.28M | 0.5% | — | New |
| Avalo Therapeutics, Inc. | AVTX | 124.7K | $1.86M | 0.4% | −$402.7K | Held |
| Alkermes plc. | ALKS | 50K | $1.77M | 0.4% | — | New |
| Opus Genetics, Inc. | IRD | 324.3K | $1.48M | 0.3% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.